The 36-month beta value for OLMA is also noteworthy at 2.07. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for OLMA is 48.58M, and at present, short sellers hold a 16.68% of that float. The average trading volume of OLMA on April 19, 2024 was 808.70K shares.
OLMA) stock’s latest price update
The stock of Olema Pharmaceuticals Inc (NASDAQ: OLMA) has decreased by -7.56 when compared to last closing price of 10.71.Despite this, the company has seen a loss of -14.29% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-08 that SAN FRANCISCO, April 08, 2024 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a panel on “Breast Cancer – Shifting an Entrenched Paradigm” at the 2024 CG Horizons in Oncology Virtual Conference on Monday, April 15, 2024, at 2:00 p.m. ET.
OLMA’s Market Performance
OLMA’s stock has fallen by -14.29% in the past week, with a monthly drop of -14.29% and a quarterly drop of -11.69%. The volatility ratio for the week is 6.67% while the volatility levels for the last 30 days are 5.93% for Olema Pharmaceuticals Inc. The simple moving average for the past 20 days is -10.57% for OLMA’s stock, with a -18.12% simple moving average for the past 200 days.
Analysts’ Opinion of OLMA
Many brokerage firms have already submitted their reports for OLMA stocks, with Goldman repeating the rating for OLMA by listing it as a “Buy.” The predicted price for OLMA in the upcoming period, according to Goldman is $24 based on the research report published on April 02, 2024 of the current year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see OLMA reach a price target of $20. The rating they have provided for OLMA stocks is “Buy” according to the report published on January 30th, 2024.
Oppenheimer gave a rating of “Outperform” to OLMA, setting the target price at $21 in the report published on July 21st of the previous year.
OLMA Trading at -22.14% from the 50-Day Moving Average
After a stumble in the market that brought OLMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.35% of loss for the given period.
Volatility was left at 5.93%, however, over the last 30 days, the volatility rate increased by 6.67%, as shares sank -14.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.11% lower at present.
During the last 5 trading sessions, OLMA fell by -14.29%, which changed the moving average for the period of 200-days by +13.01% in comparison to the 20-day moving average, which settled at $10.98. In addition, Olema Pharmaceuticals Inc saw -29.44% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OLMA starting from Harmon Cyrus, who sale 20,000 shares at the price of $10.97 back on Mar 28 ’24. After this action, Harmon Cyrus now owns 826,283 shares of Olema Pharmaceuticals Inc, valued at $219,400 using the latest closing price.
Harmon Cyrus, the Director of Olema Pharmaceuticals Inc, sale 25,000 shares at $12.41 during a trade that took place back on Feb 29 ’24, which means that Harmon Cyrus is holding 846,283 shares at $310,309 based on the most recent closing price.
Stock Fundamentals for OLMA
The total capital return value is set at -0.41. Equity return is now at value -42.82, with -39.24 for asset returns.
Based on Olema Pharmaceuticals Inc (OLMA), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -34.64. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 79.76.
Currently, EBITDA for the company is -104.58 million with net debt to EBITDA at 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.33.
Conclusion
In summary, Olema Pharmaceuticals Inc (OLMA) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
